Referências
Principais artigos
Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586-597. Resumo
Public Health England. Parvovirus B19: guidance, data and analysis. May 2017 [internet publication].Texto completo
Cherry JD. Parvovirus infections in children and adults. Adv Pediatr. 1999;46:245-69. Resumo
American Academy of Pediatrics. Parvovirus B19 (Erythema Infectiosum, fifth disease). 32nd ed. In: Kimberlin DW, Barnett ED, Lynfield R, et al. eds. Red book: 2021 report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2021:593-6.
Centers for Disease Control and prevention. Parvovirus B19 and fifth disease. Nov 2019 [internet publication].Texto completo
Artigos de referência
1. Hashimoto H, Yuno T. Parvovirus B19-associated purpuric-petechial eruption. J Clin Virol. 2011;52:269-271. Resumo
2. Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586-597. Resumo
3. Shimohata H, Higuchi T, Ogawa Y, et al. Human parvovirus B19-induced acute glomerulonephritis: a case report. Ren Fail. 2013;35:159-162. Resumo
4. Huang RJ, Varr BC, Triadafilopoulos G. Acute fulminant hepatic failure associated with parvovirus B19 infection in an immunocompetent adult. Dig Dis Sci. 2012;57:2811-2813. Resumo
5. Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis. 2009;48:1713-1723.Texto completo Resumo
6. Barah F, Whiteside S, Batista S, et al. Neurological aspects of human parvovirus B19 infection: a systematic review. Rev Med Virol. 2014;24:154-168.Texto completo Resumo
7. Molina KM, Garcia X, Denfield SW, et al. Parvovirus B19 myocarditis causes significant morbidity and mortality in children. Pediatr Cardiol. 2013;34:390-397. Resumo
8. Public Health England. Parvovirus B19: guidance, data and analysis. May 2017 [internet publication].Texto completo
9. Cherry JD. Parvovirus infections in children and adults. Adv Pediatr. 1999;46:245-69. Resumo
10. Public Health England. Parvovirus B19 activity in England and Wales. May 2019 [internet publication].Texto completo
11. Lowry SM, Brent LH, Menaldino S, et al. A case of persistent parvovirus B19 infection with bilateral cartilaginous and ligamentous damage to the wrists. Clin Infect Dis. 2005 Aug 15;41(4):e42-4.Texto completo Resumo
12. Azzi A, Morfini M, Mannucci PM. The transfusion associated transmission of Parvovirus B19. Transfus Med Rev. 1999;13:194-204. Resumo
13. Yu MY, Alter HJ, Virata-Theimer ML, et al. Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion. 2010;50:1712-1721. Resumo
14. Cohen B. Parvovirus B19: an expanding spectrum of disease. BMJ. 1995;311:1549-1552.Texto completo Resumo
15. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med. 1994;330:1192-1196.Texto completo Resumo
16. Anand A, Gray ES, Brown T, et al. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med. 1987;316:183-186. Resumo
17. American Academy of Pediatrics. Parvovirus B19 (Erythema Infectiosum, fifth disease). 32nd ed. In: Kimberlin DW, Barnett ED, Lynfield R, et al. eds. Red book: 2021 report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2021:593-6.
18. Bernstein DI, Sahly HM, Keitel WA, et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011;29:7357-7363. Resumo
19. Bansal GP, Hatfield JA, Dunn FE, et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis. 1993;167;1034-1044. Resumo
20. Ballou WR, Reed JL, Noble W, et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis. 2003;187;675-678.Texto completo Resumo
21. Chandramouli S, Medina-Selby A, Coit D, et al. Generation of a parvovirus B19 vaccine candidate. Vaccine. 2013;31:3872-3878. Resumo
22. Public Health England. Investigation, diagnosis and management of exposure to viral rash illness in pregnancy. Mar 2019 [internet publication].Texto completo
23. Koch WC, Harger JH, Barnstein B, et al. Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy. Pediatr Infect Dis J. 1998;17:489-494. Resumo
24. Rosa C. Rubella and rubeola. Semin Perinatol. 1998;22:318-322. Resumo
25. Centers of Disease Control and Prevention. Measles (rubeola): specimen collection, storage, and shipment. Jun 2022 [internet publication].Texto completo
26. Stoeckle MY. The spectrum of human herpesvirus 6 infection: from roseola infantum to adult disease. Annu Rev Med. 2000;51:423-430. Resumo
27. Bratton RL, Nesse RE. St Anthony's Fire: diagnosis and management of erysipelas. Am Fam Physician. 1995;51:401-404. Resumo
28. Crabol Y, Terrier B, Rozenberg F, et al; Groupe d'experts de l'Assistance Publique-Hôpitaux de Paris. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56:968-977. Resumo
29. Miller E, Fairley CK, Cohen BJ, et al. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol. 1998;105:174-178. Resumo
30. Gratacos E, Torres PJ, Vidal J, et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis. 1995;171:1360-1363. Resumo
31. Fairley CK, Smoleniec JS, Caul OE, et al. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19. Lancet. 1995;346:1335-1337. Resumo
32. Selbing A, Jesefsson A, Dahlo LO, et al. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet. 1995;345:660-661. Resumo
33. Centers for Disease Control and prevention. Parvovirus B19 and fifth disease. Nov 2019 [internet publication].Texto completo
O uso deste conteúdo está sujeito ao nosso aviso legal